GlassScriptPhysician profile
Prashanth S Katrapati
NPI 1497941546
$20,775.95
in general payments reported to CMS, 2019-2025
46 companies · $5,509 in 2025
The $5,509 reported for 2025 was more than what 84% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $1,471 · 2021: $2,943 · 2022: $2,760 · 2023: $2,876 · 2024: $2,822 · 2025: $5,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,017 · Travel and Lodging: $4,170 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,017.21 |
| Travel and Lodging | $4,170.25 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $2,388.88 | 2025 | Angiovac, Alphavac |
| Medtronic, INC. | $1,906.12 | 2021-2025 | Micra, Onyx Frontier, Resolute Onyx |
| Shockwave Medical, INC | $1,576.28 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $1,284.30 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,280.54 | 2019-2025 | Optis, Coroflow, Advisor |
| Amgen INC. | $1,207.10 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $1,106.65 | 2019-2025 | Biomonitor, Solia, Selectra |
| Boston Scientific Corporation | $995.04 | 2019-2025 | Watchman Flx, General - Atherectomy, Rotablator Rotational Atherectomy System Console Kit |
| Novartis Pharmaceuticals Corporation | $917.62 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $864.96 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $750.91 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $719.36 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $678.19 | 2019-2025 | Andexxa, Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.69 | 2019-2025 | Jardiance |
| Pfizer INC. | $618.33 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Katrapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.